Podcasts about virtual clinical trials

In this episode of BioTalk Unzipped, hosts Gregory Austin and Chad Briscoe continue their conversation with Dr. Nathan Teuscher, a seasoned expert in clinical pharmacology and pharmacometrics. They discuss the challenges and opportunities presented by new technologies, particularly in drug development and patient engagement. The conversation highlights the evolution of pharmaceuticals, and the potential of virtual clinical trials. In this conversation, Nathan Teuscher discusses the importance of optimizing drug dosages in oncology, the challenges faced in cell therapy, and the complexities of treating immunocompromised patients. He emphasizes the need for collaboration in the scientific community and shares his perspective on measuring success in life and career. Additionally, Nathan talks about his podcast, Clinical Pharmacology (https://creators.spotify.com/pod/show/clinical-pharmacology), which aims to educate listeners on clinical pharmacology and related topics. Chapters 00:51 The Changing Landscape of Pharmaceuticals 03:49 Virtual Clinical Trials and Patient Engagement 08:06 Optimizing Drug Dosage in Oncology 10:55 New News! - FDA Approvals (Mesoblast) and Challenges in Cell Therapy 14:26 The Complexities of Cell Therapy 17:33 Navigating Immunocompromised States in Treatment 20:09 Advice to Young Scientists in Biopharma  23:04 Defining Success in Life and Career 24:47 The Purpose and Impact of Nathan's Podcast, Clinical Pharmacology HOW TO REACH US: Nathan Teuscher https://www.linkedin.com/in/nathanteuscher/  Aplos Analytics - https://aplosanalytics.com/  Email: nathan@aplosanalytics.com Nathan Teuscher's Podcast: Clinical Pharmacology Podcast https://teuschersolutions.com/  Collaboration with BioTalk Unzipped (Ep. 40) https://podcasts.apple.com/us/podcast/collaboration-with-biotalk-unzipped-ep-40/id1695617234?i=1000682122951  Podcast (on Spotify): https://creators.spotify.com/pod/show/clinical-pharmacology Podcast (on Apple): https://podcasts.apple.com/us/podcast/clinical-pharmacology-podcast-with-nathan-teuscher/id1695617234 Dr. Chad Briscoe https://www.linkedin.com/in/chadbriscoe/  Celerion - https://www.celerion.com/   Gregory Austin https://www.linkedin.com/in/gregoryaustin1/  ECI - https://eci-rx.com /  Takeaways Nathan Teuscher has over 20 years of experience in clinical pharmacology and pharmacometrics. Virtual clinical trials can enhance patient engagement and diversity in research. Finding the right dosage is a critical challenge in drug development. Project Optimus aims to redefine oncology drug development practices. AI and data analysis can help identify ideal candidates for clinical trials. Ethical considerations are paramount in the use of patient data for research. The right dose for each patient varies significantly. Understanding individual immune system capacities is crucial in treatment. Collaboration is key to success in the scientific community. Success is measured by the happiness of loved ones. Finding joy in helping others is essential for career fulfillment. Podcasts serve as valuable educational resources. Engaging with diverse disciplines enhances scientific understanding. Sound Bites “If you want to be successful, seek first to understand, then be understood.” “If you're looking to help people and in collaboration, you'll be successful.” “Success in life is the happiness of loved ones around you.” New News Story:  After two rejections, FDA approves Mesoblast's first-of-its-kind cell therapy https://www.fiercepharma.com/pharma/fda-nod-gvhd-cell-therapy-gives-australian-biotech-mesoblast keywords BioTalk, pharmacology, AI in pharma, drug development, Nathan Teuscher, pharmacometrics, virtual clinical trials, clinical research, pharmaceuticals, virtual trials, healthcare innovation, drug development, patient engagement, medical technology, drug dosage, oncology, FDA approval, cell therapy, immunocompromised, collaboration, success, clinical pharmacology, podcast, healthcare

Researchers at the University of Manchester and The Christie cancer hospital are leveraging artificial intelligence to simulate clinical trials, significantly enhancing the speed, safety, and cost-effectiveness of cancer research. With a £5.9 million funding boost from Cancer Research UK, this innovative approach uses real-life data to create virtual patients, allowing for precise testing of radiotherapy treatments. This collaboration aims to develop AI algorithms for personalized radiotherapy, improving treatment outcomes and reducing side effects, while also accelerating research and innovation in cancer care.

Dr. Michael Gibson discusses The Heartline Trial and a new paradigm in conducting virtual clinical trials.

What are decentralized clinical trials? What are the benefits of decentralized clinical trials? Why are decentralized clinical trials the way of the future?Emily Mitchell,  Executive Director of ICON's DCT team, discusses the benefits of these trials and what needs to be considered to ensure these benefits are realized. Emily Mitchell has over 15 years of experience working in the CRO industry in Data Management, Project Management, and Clinical Operations. During her tenure at ICON, Emily partnered with an actigraphy vendor to run a pilot study with employees on the wear compliance and comparison of a medical grade activity tracker to a commercial grade version. Before the pandemic, Emily helped set up and support the first fully decentralized trial at ICON. She has continued to present at various conferences around the best practices for decentralized studies, ensuring minimized patient and site burden while optimizing data capture. Emily is an active member of the Society of Clinical Data Management (SCDM) and has presented about decentralized trials at numerous conferences.ICON is the only CRO to offer all services (without the need to contract third-party services or technology) and deliver end-to-end integrated decentralized clinical trial solutions.  ICON supported the delivery of the first decentralized clinical trial that has had positive published results in a medical journal – Nature MedicineWe are talking about⭐ Decentralized clinical trials⭐How they benefit patients⭐The impact on budgeting⭐Successful deployment of clinical trials an⭐ Much, much moreYoutube

Life at Kessler Foundation - Episode 6 Read the transcript at https://kesslerfoundation.org/sites/default/files/2022-01/Jacqueline%20Leddy%20on%20Moving%20from%20Onsite%20to%20Cyberspace_Conducting%20Virtual%20Clinical%20Trials-Ep6-TRANSCRIPT.pdf In this episode, Jacqueline (Jackie) Leddy, a research assistant in our Centers for Neuropsychology and Neuroscience Research and Traumatic Brain Injury Research was interviewed by Joan Banks-Smith, Creative Producer for Kessler Foundation. Jackie discusses how she and fellow team members are motivated by their efforts, which could change people's lives for the better, and how working at Kessler Foundation has provided her with a chance to learn, grow and explore how clinical trials are done. She has been instrumental in transitioning recruitment and operation of a traumatic brain injury clinical trial from onsite to completely virtual over the past 18 months. This clinical trial focuses on facial affect recognition and emotional processing for children from age nine to seventeen. The revamped recruiting process has opened the door to a wider range of participants, going from local to a global mix. Learn more about Jacqueline at https://kesslerfoundation.org/about-us/foundation-staff/jacqueline-leddy and the Center for Traumatic Brain Injury Research at https://kesslerfoundation.org/research/center-traumatic-brain-injury and Center for Neuropsychology and Neuroscience Research at https://kesslerfoundation.org/research/center-neuropsychology-and-neuroscience-research Interested in participating in the study mentioned in this podcast? Go to https://kesslerfoundation.org/research/studies/emotional-processing-intervention-children-tbi Interested in a career at Kessler Foundation, go to https://kesslerfoundation.org/careers ======================================================= Keywords: Facial Affect Recognition - Not being able to accurately detect and respond to the emotions conveyed in facial expressions of others is a significant issue for individuals with mental health problems. Facial affect recognition is essential for successful social interaction. Emotional Processing - Emotional processing is the ability of people to process stress and other extreme events and move past them over time. When individuals are unable to process or reduce those emotions, they may develop phobias and other mental issues. Functional magnetic resonance imaging (fMRI) – a specialized MRI scanner that measures the small changes in blood flow that occur with brain activity. ======================================================= Tuned into our podcast series lately? Join our listeners in 90 countries who enjoy learning about the work of Kessler Foundation. Be sure to subscribe to our SoundCloud channel “KesslerFoundation” for more research updates. Follow us on Facebook, Twitter, and Instagram. Listen to us on Apple Podcasts, Spotify, SoundCloud, or wherever you get your podcasts. This podcast was recorded remotely on Tuesday, September 14, 2021, and was edited and produced by Joan Banks-Smith, Creative Producer for Kessler Foundation.

On this episode, Greg Horne interviews Craig Lipset, advisor, advocate and educator in the area of decentralized clinical trials and the former head of clinical innovation at Pfizer. During his time at Pfizer, Craig helped design and lead the first fully remote, decentralized trial. Surprisingly, that was more than a decade ago. In fact, Craig explains that the methods, investment and even the regulatory readiness around decentralized trials existed in the industry long before the pandemic. The lock-down disruption caused by COVID-19 in early 2020 delivered a key missing piece – meaningful adoption as the industry worked quickly to mitigate delays to ongoing research and spin up new trials to address the virus. Craig and Greg further discuss the potential for decentralized trials to make participation in clinical research more convenient and accessible to diverse and representative patient populations. Unique support is required to achieve this objective. Decentralized trial participants need specialized technical and emotional support to ensure they have a positive experience and are able to stay compliant with study protocols. In developing nations, decentralized methods can help researchers expand their work into areas where infrastructure may be lacking, but it's critical to be mindful of the digital divide and ensure that the appropriate support is provided.Craig leaves us with his perspective on the role of decentralized trials in helping health care deliver clinical research as a care option. For example, the technology offers new ways to engage with non-investigator physicians to improve engagement with community health care and democratize access to clinical research.A transcript of this episode can be found here. 

Video on Youtube: https://youtu.be/XF4Zps6dOVA Noah CraftCofounder & Co-CEO, People Sciencehttps://peoplescience.health/ (https://peoplescience.health/) Noah is a physician-scientist-entrepreneur. He is the Co-Founder/Co-CEO of People Science, focused on self-inquiry and the R&D of alternative medicines. He was previously the co-founder/CEO of Science 37, one the industry leaders in Virtual Clinical Trials. Before that, he ran a successful translational research laboratory at LA Biomed and serves as a strategic advisor to multiple biotech companies including Bexson Biomedical. He lives with his wife, son, and 2 dogs in Venice Beach, California. Belinda TanCo-founder & Co-CEO, People Sciencehttps://peoplescience.health/ (https://peoplescience.health/) Belinda Tan MD, PhD, is a physician-scientist-entrepreneur who spent her formative professional training years in Los Angeles where she currently resides. Early in her career, she began applying high impact technology ideas to clinical practice with the purpose of providing broader access to quality care. She is Co-Founder and Co-CEO of People Science, a clinical research marketplace for the R&D of alternative medicines. Dr. Tan is in the early founding team and continuing advisor to DirectDerm, the national leader delivering teledermatology services and improving health outcomes among underserved populations. She previously co-founded and served as Chief Medical Officer of Science 37, a venture-backed pioneering market leader in virtual clinical trials that led several groundbreaking first-ever FDA-regulated studies. The company's focus on bringing clinical research to people in their homes significantly improved diversity among clinical study participants, from an average of 5% to 40%. Dr. Tan is a continuing student of life, a listener, and a mentor. As a wife, mother, daughter, and sister, her first-generation American journey has enriched her appreciation of belonging to a global citizenship and of cultural competence as a healthcare provider and entrepreneur. Her personal and professional pursuits are guided by promoting inclusivity, attribution, and access. Inspired by the needs of people seeking healthcare within the LA County public health system where she trained, Dr. Tan continues to mentor medical students and residents as Assistant Clinical Professor of Medicine at Harbor-UCLA Medical Center. Her board and advisory roles involve the Los Angeles Mayor's WiSTEM (Women in STEM) Initiative, 826LA, Bexson Biomedical, Seed Health, and VisualDx. She earned her MD and PhD from UCLA and BS from MIT, with additional clinical training at the Memorial Sloan-Kettering Cancer Center and Cornell-New York Presbyterian Hospital. She lives with her husband, son, and two Labradors in Venice Beach.

Join us as Alex Hanlon, Ph.D. (Director of the Center for Biostatistics and Health Data Science at Virginia Tech,  Professor of Statistics and works closely with researchers on the Health Science and Technology Campus in Roanoke, adjacent to Carilion Clinic and the VTC School of Medicine) and Richard Bendis (Founder, President and CEO of BioHealth Innovation, Inc. and a successful entrepreneur, angel investor, innovation and technology-based economic development leader, international speaker and consultant in the technology and healthcare industries and host of BioTalk) discuss how ‘Big data requires team science.’ Additional show notes:Who funds the N3C initiative and what goes into it?The N3C is funded by the National Center for Advancing Translational Sciences (NCATS), which is part of the NIH or the National Institutes of Health. A key component of the initiative is data harmonization, which translates the differing ways that contributing hospitals store patient data into a single, common format to facilitate analyses. Participating sites add (or they will add) data on demographics, symptoms, medications, lab test results, and outcomes over a five-year period. This will enable both short- and long-term study of the impact of COVID-19 on health outcomes.Who has access to the N3C enclave data?Data access is open to all approved users, regardless of whether they contribute data. Details for gaining access can be found on the NCATS website (see link below). Researchers can request access only after their home institution has secured a data use agreement with NCATS. For those who are not associated with an institution, they will need to complete their own DUA with NCATS.https://ncats.nih.gov/n3c/about/applying-for-accessWhat kind of tools are available in the N3C enclave to support data analyses? The platform is built to support machine learning and rigorous statistical analyses using Python and R. The idea is to provide the necessary tools to address research questions using contemporary data driven techniques along with classical methods. To tackle such projects with large scale observational data requires collaboration within a team science environment, including expertise in statistics, informatics, medicine, engineering, and so on.

We continue our look at Translating Science Into Medicine by talking with Dr. Doris Fuertinger, Director of Biomathematical Modeling and Simulation at Fresenius Medical Care.  Dr. Fuertinger and her team are using complex mathematics and real-life data to create patient Avatars that can help predict an individual's physiological response to a certain treatment.  These realistic simulations of clinical trials can help overcome the limitations of traditional approaches and lead to new improvements in patient outcomes.

Joel Morse has devoted his career to building innovative companies that serve the pharmaceutical industry. His latest venture, Curavit Clinical Research runs decentralized or virtual trials, which have gotten huge in the pandemic. In this episode of the HealthBiz podcast, Joel talks about decentralized trials and why they’re growing. He also opens up about his experience building C3i, and how it led him to adventures around the world, including Joel’s involvement with the royal family in Bulgaria.

Chad Walsh, CEO of Sciteline, dives into virtual trials, including their benefits, barriers, and impact on patient-centricity. Among other things, we discuss data privacy concerns, the role of digital technologies for remote patient monitoring, eConsent, telemedicine, and much more!Schedule a meeting with Natalie Yeadon: https://www.meetwithnatalie.comNatalie Yeadon LinkedIn: https://www.linkedin.com/in/natalieyeadon/Impetus Digital Website: https://www.impetusdigital.com/Impetus Digital LinkedIn: https://www.linkedin.com/company/impetus-digital/Impetus Digital Twitter: https://twitter.com/ImpetusadboardsImpetus YouTube: https://www.youtube.com/ImpetushealthcareChad Walsh: https://www.linkedin.com/in/walshchad/Sciteline: https://sciteline.com/

Episode Highlights:The industry and operational challenges facing DCT adoption.How inconsistent nomenclature has contributed to widespread misunderstanding of DCT, and how misnomers have slowed adoption.The challenge of change management and how clarity and infrastructure can be an antidote.How DCT can help boost minority representation in clinical trial research, and why shifting those numbers requires time. How sponsors can get started with DCT and what they need to consider.Why organizational fit is critical and how to assess it.Why it's so important to talk with the patients and understand the challenges they face.Why DCT and patient-centric approaches so often go hand-in-hand.How patient engagement is changing, and why clinical trials need to adapt to that.How sites have been forgotten as stakeholders and why they're still central to clinical development.Resources:www.archemedx.comConversations in Clinical Trial Readiness serieswww.revelesclinical.comwww.linkedin.com/in/klritchwww.linkedin.com/in/r-kes-starling-rph-mba-9996214/www.clinicaltrialpodcast.comReveles' Decentralized Clinical Trial Grader: https://form.typeform.com/to/RhOpipVQhttps://www.linkedin.com/company/reveles-clinical-services

Researchers see the new acceptance of telemedicine as an opportunity during clinical trials. Along with Zoom visits, numerous sensors on participants could provide constant monitoring of health conditions without traveling to see doctors, making control better.

Anthony Costello, senior vice president of mobile health at Medidata, on what clinical trials look like when people are unable or unwilling to leave home, what this means for the race for a vaccine, and how mobile health technology is paving the way.

We had yet another American on the show today, but who is living in lovely #Barcelona - Francesca Wuttke. Jim Joyce and I are readying for a sale of our show to Spotify just like Joe Rogan #FakeNews).. Is Europe poised to drive value out of #digitalhealth? Virtual Clinical Trials and #DTx speeding ahead in this #C19 world. Emanuela Saccarola crashing the party and stealing Jim's spotlight.. and a visual of me in speedos.

Introduction [00:55]Dr. David Albert of AliveCor explains how patient-collected data can solve some of the problems facing clinical trials during the COVID-19 pandemic, as well as the long-term outlook on changes in data collection for clinical research.What is the AliveCor KardiaMobile 6L and how does it work? [01:43]The AliveCor KardiaMobile 6L is a 6-lead device for patient-collected ECG/EKG reads.How is the KardiaMobile 6L being used today in light of the COVID-19 pandemic and subsequent changes in FDA regulations? [03:21]AliveCor received the FDA’s approval for emergency use of the KardiaMobile 6L. Some drugs being tested as treatments for COVID-19 may cause QT prolongation, potentially leading to a serious cardiac arrhythmia. The KardiaMobile 6L is capable of monitoring QTc and able to keep people safe while they’re using experimental COVID-19 treatments.How can the KardiaMobile 6L make it easier for doctors to keep patients safe during COVID-19? [05:14]Taking ECGs in hospitals treating patients with coronavirus requires staff to sterilize the machine and use personal protective equipment, when those resources may be better used on the “front lines” in hospitals. Now, using the KardiaMobile 6L, patients are able to complete their own ECGs / EKGs without having to use valuable PPE or put ECG/ EKG techs at risk.How do you think we can solve the problem of successfully conducting clinical trials today during stay-at-home mandates?[07:15]There are increasing demands from sponsors who want to do virtual trials or conduct trials within unique venues, like refugee camps. In these cases, the KardiaMobile 6L can provide a solution to measure the potential impacts of a treatment on a patient’s QT interval.Should clinical trials sponsors have any concerns about the integrity of remote ECG / EKG data collection?[08:54]The KardiaMobile technology has proven that a person if trained correctly and with practice, can collect clinical-quality ECGs at home by themselves. It’s also been demonstrated that this technology can be used even in difficult populations.Do you think there’s going to be a permanent move towards at-home monitoring in clinical research following the changes put in place in response to COVID-19?[11:00]COVID-19 has been the greatest catalyst to change in primary care; for example, telemedicine has become a standard way of providing care. Patients have responded positively to it. This sentiment will likely carry over into the clinical research industry.What do you see as the benefits of at-home ECG / EKG collection by the patient?[12:28]People are more relaxed and comfortable at home, which can lead to improved data (similar to the white coat effect in collecting blood pressure data at home.) Sometimes patients may experience conditions like atrial fibrillation at home; by the time they get to the hospital or doctor, it’s passed. With personal ECG/ EKG devices, patients can document their experiences without ever going to the doctor. Remote management and remote patient monitoring are trends that are here to stay following COVID-19.How do you think remote data collection solutions will continue to evolve? What other trends do you see coming in the industry?[15:09]“Digital health” is just becoming health. The smartphone is now incorporated into every part of our lives; that’s going to become the principal entry point for many people into healthcare. Smart devices keep becoming more and more sophisticated, and we’ll continue to see more remote monitoring and attempts to prevent illness by catching issues early and encouraging changes in lifestyle and healthcare.

Today we’re in the midst of the pandemic and virtual clinical trials are likely going to be a big part of our post-COVID-19 world.  In this interview, I had the pleasure of speaking with Mike Novotny about virtual trials i.e. decentralized trials.  Mike is the founder and CEO of Medrio. Mikes brings over 20 years of experience in research and software to his eClinical SaaS vision.  Prior to founding Medrio, Mike was president of Ninaza, an EDC software company, and had previously held roles as a research associate at the U.N. and a manager of the fraud database at VISA.  He holds a BA from Stanford University and an MBA from Columbia University. Mike founded Medrio in 2005 in San Francisco. I hope you enjoy my conversation with Mike. What is a decentralized or virtual clinical trial?  Benefits of a virtual clinical trial in patient recruitment The current model of clinical trials where recruitment is done through the doctor What does it mean to conduct a decentralized or virtual clinical trial? Case Study - CNS trials and how they can benefit from going virtual A limited number of patients (smaller patient pool)  Use of social media to find eligible patients The patient does not need to travel to the doctor’s office, the caregiver goes to the patients home Medrio as a technology provider for virtual studies  eConsent Electronic data capture (EDC) Direct Data Capture (DDC) Randomization with EDC  Case Study - Cholera vaccine study in Yemen Collecting clinical data without an internet connection The downside of paper data collection DDC is a subset of eSource eSource can be EHR, DDC, ePRO, eCOA Future of EDC as we get more integrated with EHR Patient recruitment New efforts through AI Efforts through social media Genetic profiling Enabling participants to be anywhere in the world to participate in the trial Barriers to adoption Importance of monitoring in a virtual clinical trial to prevent fraud  The downside of a virtual clinical trial is the implementation Patients want their doctor to be involved New tools lead to new complications The trial does not match the decentralized model Common concerns from Sponsors Storing data on the cloud is risky Offline data management - what if the wifi goes down or there is no cellular signal Data loss - what if the tablet break Thinking in terms of relative risk Clinical trials fail 90% of the time Trial data is never looked at again Need to standardize audits to bring the cost down and improving the quality of the audit Medrio is focused on:  Speed Great tool for early phase diagnostic and device studies Customer service measured using net promoter scores eSource - Direct Data Capture (DDC) Optimism, focusing on the positive, not watching/ reading the news

Join our daily quarantine meetup: https://www.anymeeting.com/785-991-750 Text me: (949) 415-6256 My podcast is Random Musings From The Clinical Trials Guru GET THE BOOK! https://www.amazon.com/dp/1090349521/... Text "guru" to 31996 to join VIP list! My blog: http://www.TheClinicalTrialsGuru.com My business Patreon Page: http://www.patreon.com/dansfera Site Owner Academy: http://www.theclinicaltrialsguru.com/... My CRO: http://www.DSCScro.com My CRA Academy: http://www.TheCRAacademy.com My CRC Academy: http://www.thecrcacademy.com

In the midst of a pandemic, industry is looking for ways to ensure continuity of clinical trials while keeping patients safe. Virtual approaches to clinical research leverage digital technologies to bring the study to the patient, and may be – in time – a viable option for limiting personal contact and possible spread of disease during outbreak situations.In the third episode in our Coronavirus Special Edition Series, David Thompson, Senior Vice President, Real World Evidence at Syneos Health discusses potential applications for virtual research in the real world, and the pros and cons of going virtual, offering a glimpse into the future of clinical research.  For more detail on the promise of virtual trials, read our latest paper “Virtual Research: What It Is and What It's Doing in the Real-World Setting.”Stay tuned for more installments of the Coronavirus Special Edition Series, which will explore, from an operational standpoint, the impact of COVID-19 on the biopharma industry, the challenges for rapid R&D in an outbreak environment, and the opportunities to leverage technology and innovation to address these critical issues. Additional materials and insights can also be found in our COVID-19 Resource Center.If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you're hearing?  Be sure to rate and review us!  We want to hear from you!  If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com. * This episode was recorded on 3/16/2020.

A follow-up to Virtual Trials, Part 1, Dr. Kingsley continues his discussion on how virtual clinical trials are revolutionizing research. Find out what's driving this innovation.

Revolutionizing research is all about making the process better of how we do research - to benefit patients, physicians, to enhance how quickly we are able to help patients in need, and innovate faster in healthcare. That’s what revolutionizing research is about. Many times it is not about the little things we do to make it better, it’s about the dramatic things we can do. The use of virtual trials is just one way we can revolutionize research!

Text "guru" to 31996http://www.TheClinicalTrialsGuru.comSite Owner Academy: http://www.theclinicaltrialsguru.com/site-owner-academy/My CRO: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy Research News Site: http://www.TheClinicalScoop.comCall/Text: (949) 415-6256Follow Me On:SnapChat: username is dansferaInstagram: https://instagram.com/dansferaTwitter: https://twitter.com/TheRealDanSferaFacebook: https://www.facebook.com/dansferaLinkedIn: https://www.linkedin.com/profile/view...My iTunes Podcast: https://itunes.apple.com/us/podcast/random-musings-from-the-clinical-trials-guru/id1245751329My Stitcher Podcast: http://www.stitcher.com/podcast/dan-s...Google Play Podcast: https://playmusic.app.goo.gl/?ibi=com.google.PlayMusic&isi=691797987&ius=googleplaymusic&link=https://play.google.com/music/m/Ikoltbj2pxcbscwwajoixxdhix4?t%3DRandom_Musings_From_The_Clinical_Trials_Guru%26pcampaignid%3DMKT-na-all-co-pr-mu-pod-16

Challenge Discussed : Healthcare and Life Science industry in particular has been slow to ride the wave of digital transformation.But 2019 will be promising and witness a rapid transition with the wider acceptance of virtual care, value based care and disruptive technologies.Speaker : Khushbu JainKey Findings- Personalized Medicine, Predictive Analytics, Decentralized Healthcare, Reimbursement Headwinds, Data – Driven HealthcarePredictions- Drug Discovery, Clinical Development IT, Bio-analytical, cGMP, oncology, rare diseases, neuroscience, Liquid Biopsy, Big Data, EUIVDR, PAMA, Connected Lab Technology to Watch - Digital- IIoT, big data and analytics, AI, and cloud systems Growth Opportunity - CANCER IMMUNOTHERAPY; CELL BANKING; SINGLE USE IN BIOLOGICS MANUFACTURING; NGS; LIQUID BIOPSY; POINT-OF-CARE TESTS; GENOMICSPharmaceutical & Biotechnology; In-Vitro Diagnostics (IVD) & Research Tools, Healthcare IT, Life Sciences Business Trends,Life Sciences Technology TrendsKey Takeaways :Well, It is true that it takes decades for complete transition and a trend to set in, for it to become the norm, but the foundational elements that signal the shift are taking shape today.We are more cognizant of the rapidly declining return on investment on R&D and growing complexity with precision medicine catering to selected population groups.We are more cognizant of the fact that healthcare is shifting from treatment to wellness and patients are increasingly becoming the pivotal decision makers.We, within the industry are experiencing the huge impact of non-traditional competitors and how technology companies are upending the way we function.Collectively, these trends create a mandate for life sciences companies to become more efficient, nimble, and patient-centric in 2019.Acknowledging these challenges is not enough, we need to ask the next logical question- what next and how do we stay ahead of the curve?The first reality is that the companies will have to embrace digital-first mindset and change everything from the way R&D is conducted, to how clinical trials are designed, to how new products are commercialized.Companies will have to whole-heartedly embrace Cognitive, artificial intelligence, multi-omics and real world data at every single step to extract the full potential of digital revolution.Secondly, companies will have to recalibrate their M&A strategy on two fronts- A) focus on building the depth of the portfolio through acquisitions and B), embrace new types of partnerships and collaborations.Life Science companies will have to increasingly foster and support the start-up 2.0 ecosystem and forge unconventional partnerships with them.But more importantly it is the incorporation of the patient voice throughout the lifecycle of therapy development, which will propel growth in 2019.Against the backdrop of these imperatives we dive deeper into more specific and immediately realizable growth opportunities in our 2019 outlook for the life sciences industry.We discuss specifics of Virtual Clinical Trials and how it is Challenging Traditional Vendors, we identify opportunity in Single-use Technology and its ability to Enable Decentralization of Cell & Gene Therapy manufacturing, we dive deeper into Growth of direct to consumer genetic testing Market, liquid biopsy and IVF in APAC region.There are several intrinsic and extrinsic challenges that are altering conventional ways of doing a business, but the good news is there are just as many opportunities.The key for the life science industry is to make use of ongoing breakthroughs in the fundamental science behind diagnosis and cure, leverage innovation from our cohorts and keep an eye out for opportunities that surface.Even incremental changes in 2019 can pave way for monumental shifts in the future.On that positive note, I hope you have enjoyed this session.Please join us for future podcasts and become a member of our Leadership Council by emailing us at digital@frost.com.Thank you for your time. Have a nice day!Website: www.frost.com See acast.com/privacy for privacy and opt-out information.

http://www.TheClinicalTrialsGuru.comSite Owner Academy: http://www.theclinicaltrialsguru.com/site-owner-academy/My CRO: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy Research News Site: http://www.TheClinicalScoop.comCall/Text: (949) 415-6256Follow Me On:SnapChat: username is dansferaInstagram: https://instagram.com/dansferaTwitter: https://twitter.com/TheRealDanSferaFacebook: https://www.facebook.com/dansferaLinkedIn: https://www.linkedin.com/profile/view...My iTunes Podcast: https://itunes.apple.com/us/podcast/random-musings-from-the-clinical-trials-guru/id1245751329My Stitcher Podcast: http://www.stitcher.com/podcast/dan-s...Google Play Podcast: https://playmusic.app.goo.gl/?ibi=com.google.PlayMusic&isi=691797987&ius=googleplaymusic&link=https://play.google.com/music/m/Ikoltbj2pxcbscwwajoixxdhix4?t%3DRandom_Musings_From_The_Clinical_Trials_Guru%26pcampaignid%3DMKT-na-all-co-pr-mu-pod-16